ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 10/04/2011

Grantor: CDER IND/IDE Number: 71,576 Serial Number:

# Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

This study has been completed.

| | |
|---|---|
| Sponsor: | Gilead Sciences |
| Collaborators: | |
| Information provided by (Responsible Party): | Gilead Sciences |
| ClinicalTrials.gov Identifier: | NCT00307489 |

## Purpose

This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently being treated with adefovir dipivoxil (Hepsera) for chronic hepatitis B who have persistent viral replication (detectable hepatitis B virus deoxyribonucleic acid [HBV DNA]).

Subjects with confirmed (within 4 weeks) plasma HBV DNA ≥ 400 copies/mL during double blind treatment at Week 24 or any time thereafter have the option of receiving 12 weeks of open-label FTC/TDF which may be continued through the end of the 168-week treatment period if there is a virologic response (HBV DNA < 400 copies/mL). Alternatively, subjects with confirmed HBV DNA < 400 copies/mL at or any time after Week 24 of double-blind treatment may continue blinded therapy up to Week 168 at the discretion of the investigator. If, in the investigator's opinion, it is felt that continued blinded treatment beyond 24 weeks in subjects with confirmed HBV DNA ≥ 400 copies/mL is not beneficial, the subject may discontinue the study and begin commercially available HBV therapy rather than initiate open-label FTC/TDF.

| Condition | Intervention | Phase |
|---|---|---|
| Chronic Hepatitis B | Drug: tenofovir DF<br>Drug: emtricitabine /tenofovir DF | Phase 2 |

Study Type: Interventional
Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Investigator, Outcomes Assessor), Randomized, Safety/Efficacy Study

Official Title: A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adefovir Dipivoxil for Chronic Hepatitis B and Having Persistent Viral Replication

Further study details as provided by Gilead Sciences:

Primary Outcome Measure:

- Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 [Time Frame: 48 weeks] [Designated as safety issue: No]
- Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]

Secondary Outcome Measures:

- Change From Baseline in log10 Plasma HBV DNA Levels at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
- Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
- Percentage of Participants With Normal ALT at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  ULN for males = 43 U/L; 34 U/L for females
- Percentage of Participants With Normalized ALT at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Subjects with elevated ALT at baseline that return to normal by Week 48.
- Hepatitis B Early Antigen (HBeAg) Loss at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.
- HBeAg Seroconversion at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline.
- HBsAg Loss at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
- Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48 [Time Frame: 48 Weeks] [Designated as safety issue: No]
  Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline.
- Change From Baseline in log10 Plasma HBV DNA Levels at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
- Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
- Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
- Percentage of Participants With Normal ALT at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  ULN for males = 43 U/L; ULN for females = 34 U/L
- Percentage of Participants With Normalized ALT at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  Subjects with elevated ALT at baseline that return to normal by Week 48.
- Hepatitis B Early Antigen (HBeAg) Loss at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.
- Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.
- HBsAg Loss at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
- Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168 [Time Frame: 168 weeks] [Designated as safety issue: No]
  P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.

Enrollment: 106
Study Start Date: March 2006
Primary Completion Date: January 2008
Study Completion Date: October 2010

| Arms | Assigned Interventions |
|---|---|
| Experimental: 1<br>TDF | Drug: tenofovir DF<br>300 mg tablet, once daily (QD) |
| Experimental: 2<br>FTC/TDF | Drug: emtricitabine /tenofovir DF<br>emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet) |

## Eligibility

Ages Eligible for Study: 18 Years to 69 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

### Criteria

Inclusion Criteria:

- 18 through 69 years of age, inclusive
- Chronic HBV infection, defined as positive serum HBsAg for at least 6 months
- Active chronic HBV infection with all the following:
    a. Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not more than 96 weeks)
    b. HBeAg positive or negative at screening
    c. Plasma HBV DNA >/= 1000 copies/mL at screening (irrespective of HBeAg status)
    d. Serum ALT less than 10 times the upper limit of normal (ULN)
    e. Calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault formula
    f. Hemoglobin at least 8 g/dL
    g. Neutrophils at least 1,000 /mm3
- Nucleoside naive except for lamivudine (>/= 12 weeks of therapy)
- Negative serum beta human chorionic gonadotropin
- Compliant with adefovir dipivoxil
- Willing and able to provide written informed consent

Exclusion Criteria:

- Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
- Male or females of reproductive potential who are unwilling to use an effective method of contraceptive while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used
- Decompensated liver disease defined as conjugated bilirubin greater than 1.5 times ULN, prothrombin time (PT) greater than 1.5 times ULN, platelets less than 75,000/mm3, serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
- Prior use of tenofovir DF or entecavir
- Received treatment with interferon or pegylated interferon within 6 months of the screening visit
- Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater than 50 ng/mL or by any other standard of care measure.
- Co-infection with HCV (based on serology), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)

- Significant renal, cardiovascular, pulmonary, or neurological disease.
- Received solid organ or bone marrow transplantation.
- Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion
- Has proximal tubulopathy
- Known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation excipients

## Contacts and Locations

Locations

United States, California

San Francisco, California, United States, 94115
San Jose, California, United States, 95128

United States, New York

Flushing, New York, United States, 11355
New York, New York, United States, 10013
New York, New York, United States, 10021
New York, New York, United States, 10016

United States, Pennsylvania

Philadelphia, Pennsylvania, United States, 19107

United States, Virginia

Fairfax, Virginia, United States, 22031
Norfolk, Virginia, United States, 23502
Richmond, Virginia, United States, 23249

France

Angers, France, 49933
Clichy, France, 92110
Lille, France, 59037
Lyon, France, 69288
Marseille, France, 13285
Rouen, France, 76031
Strasbourg, France, 67091

Germany

Berlin, Germany, 13353
Berlin, Germany, 10969
Bonn, Germany, 53105
Erlangen, Germany, 91054
Essen, Germany, 45122
Frankfurt, Germany, 60590
Hamburg, Germany, 20999
Hannover, Germany, 30623
Herne, Germany, 44623
Munchen, Germany, 81377

Spain

Sevilla, Spain, 41014

Investigators

| | | |
|---|---|---|
| Study Director: | Stephen J Rossi, PharmD | Gilead Sciences |

## More Information

Results Publications:


van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006 Aug;44(2):318-25.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008 Mar;48(3):383-6. doi: 10.1016/j.jhep.2007.12.006. Epub 2007 Dec 31.

Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008 Mar;48(3):391-8. doi: 10.1016/j.jhep.2007.09.020. Epub 2008 Jan 3.

van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010 Jan;51(1):73-80. doi: 10.1002/hep.23246.

Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.


| | |
|---|---|
| Responsible Party: | Gilead Sciences |
| Study ID Numbers: | GS-US-174-0106 |
| Health Authority: | United States: Food and Drug Administration |

# Study Results

## Participant Flow

| | |
|---|---|
| Recruitment Details | A total of 106 subjects were randomized (105 of which were subsequently treated) across 28 study centers in the US, Germany, France and Spain between 24 April 2006 and 07 March 2007. |

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Baseline Through Week 48

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Started | 53 | 52 |
| Completed | 52 [1] | 50 [2] |
| Not Completed | 1 | 2 |
| Lost to Follow-up | 0 | 1 |
| Physician Decision | 1 | 0 |
| Withdrawal by Subject | 0 | 1 |

[1] 16 of the 52 subjects switched to open-label FTC/TDF prior to Week 48.
[2] 9 of the 50 subjects switched to open-label FTC/TDF prior to Week 48.

Week 48 Through Week 168

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Started | 52 | 50 |
| Completed | 46 [1] | 44 [2] |
| Not Completed | 6 | 6 |
| Adverse Event | 1 | 0 |
| Physician Decision | 1 | 0 |
| Withdrawal by Subject | 1 | 2 |
| Lack of Efficacy | 2 | 2 |
| Death | 0 | 1 |
| Lost to Follow-up | 0 | 1 |
| Seroconversion | 1 | 0 |

[1] 11 of the 46 subjects switched to open-label FTC/TDF prior to Week 168.
[2] 5 of the 44 subjects switched to open-label FTC/TDF prior to Week 168.

## Baseline Characteristics

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Baseline Measures

| | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Number of Participants | 53 | 52 | 105 |
| Age, Continuous<br>[units: years]<br>Mean (Standard Deviation) | 40 (11.4) | 39 (10.4) | 39 (10.9) |
| Gender, Male/Female<br>[units: participants] | | | |
| Female | 15 | 10 | 25 |
| Male | 38 | 42 | 80 |
| Race/Ethnicity, Customized<br>[units: Participants] | | | |
| Asian | 26 | 18 | 44 |
| Black or African American | 2 | 8 | 10 |
| White | 23 | 21 | 44 |
| Other | 2 | 5 | 7 |
| Previous Lamivudine Experience<br>[units: participants] | | | |
| Yes | 30 | 31 | 61 |
| No | 23 | 21 | 44 |
| Baseline HBV DNA<br>[units: log10 copies/mL]<br>Mean (Standard Deviation) | 6.06 (1.430) | 5.87 (1.779) | 5.97 (1.607) |

# Outcome Measures

1. Primary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 |
| Measure Description | |
| Time Frame | 48 weeks |
| Safety Issue? | No |

Analysis Population Description

Randomized and Treated (RAT) subjects at Week 48 - Non-Completers=Failure (ie, includes subjects who switched to open-label FTC/TDF at or after Week 24)

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 52 |
| Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48<br>[units: percentage of participants] | 75.5 | 69.2 |

Statistical Analysis 1 for Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | .544 |
| | Comments | P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use. |

| | | |
|---|---|---|
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

2. Primary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48 |
| Measure Description | |
| Time Frame | 48 Weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | January 2009 |

Analysis Population Description
RAT Analysis Set Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 52 |
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48<br>[units: percentage of participants] | 81.1 | 80.8 |

Statistical Analysis 1 for Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.988 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

3. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Change From Baseline in log10 Plasma HBV DNA Levels at Week 48 |
| Measure Description | |
| Time Frame | 48 Weeks |
| Safety Issue? | No |

Analysis Population Description
RAT Analysis Set

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 52 | 50 |
| Change From Baseline in log10 Plasma HBV DNA Levels at Week 48<br>[units: log10 copies/mL]<br>Mean (Standard Deviation) | -3.58 (1.290) | -3.34 (1.753) |

Statistical Analysis 1 for Change From Baseline in log10 Plasma HBV DNA Levels at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |

| | | |
|---|---|---|
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.208 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Other [van Elteren] |
| | Comments | [Not specified] |

4. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48 |
| Measure Description | |
| Time Frame | 48 Weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | January 2009 |

Analysis Population Description
RAT Analysis Set

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 50 | 50 |
| Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48<br>[units: U/mL]<br>Mean (Standard Deviation) | -21.6 (54.53) | -41.4 (151.67) |

Statistical Analysis 1 for Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.712 |
| | Comments | Controlling for baseline HBeAg and prior lamivudine use. |
| | Method | Other [van Elteren] |
| | Comments | [Not specified] |

5. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Normal ALT at Week 48 |
| Measure Description | ULN for males = 43 U/L; 34 U/L for females |
| Time Frame | 48 Weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | January 2009 |

Analysis Population Description

RAT Analysis Set Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 51 | 52 |
| Percentage of Participants With Normal ALT at Week 48<br>[units: percentage of participants] | 66.7 | 73.1 |

Statistical Analysis 1 for Percentage of Participants With Normal ALT at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.423 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

6. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Normalized ALT at Week 48 |
| Measure Description | Subjects with elevated ALT at baseline that return to normal by Week 48. |
| Time Frame | 48 Weeks |
| Safety Issue? | No |

Analysis Population Description

RAT Analysis Set - subjects with ALT above ULN at baseline. Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 27 | 26 |
| Percentage of Participants With Normalized ALT at Week 48<br>[units: percentage of participants] | 40.7 | 61.5 |

Statistical Analysis 1 for Percentage of Participants With Normalized ALT at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.109 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

7. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Hepatitis B Early Antigen (HBeAg) Loss at Week 48 |
| Measure Description | Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline. |
| Time Frame | 48 Weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | January 2009 |

Analysis Population Description

RAT Analysis Set with Positive HBeAg at Baseline. Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 38 | 39 |
| Hepatitis B Early Antigen (HBeAg) Loss at Week 48 [units: participants] | 3 | 3 |

Statistical Analysis 1 for Hepatitis B Early Antigen (HBeAg) Loss at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.952 |
| | Comments | [Not specified] |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | Controlling for baseline HBeAg and prior lamivudine use. |

8. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | HBeAg Seroconversion at Week 48 |
| Measure Description | Defined as having negative serum HBeAg and positive serum antibody to HBeAg [anti-HBe] for subjects with positive serum HBeAg at baseline. |
| Time Frame | 48 Weeks |
| Safety Issue? | No |

Analysis Population Description

RAT Analysis Set with Positive Baseline HBeAg. Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 38 | 39 |
| HBeAg Seroconversion at Week 48<br>[units: participants] | 2 | 3 |

Statistical Analysis 1 for HBeAg Seroconversion at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.655 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

9. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | HBsAg Loss at Week 48 |
| Measure Description | Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. |
| Time Frame | 48 Weeks |
| Safety Issue? | No |

Analysis Population Description

RAT Analysis Set Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 51 |
| HBsAg Loss at Week 48<br>[units: participants] | 1 | 0 |

Statistical Analysis 1 for HBsAg Loss at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.401 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

10. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48 |
| Measure Description | Defined as having negative serum HBsAg and positive serum antibody to HBsAg [anti-HBs] for subject with positive serum HBsAg at baseline. |
| Time Frame | 48 Weeks |
| Safety Issue? | No |

Analysis Population Description

RAT Analysis Set Non-Completers=Failure

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 51 |
| Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48<br>[units: participants] | 1 | 0 |

Statistical Analysis 1 for Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.401 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

11. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Change From Baseline in log10 Plasma HBV DNA Levels at Week 168 |
| Measure Description | |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description

Non-completers = failure analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 52 |

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Change From Baseline in log10 Plasma HBV DNA Levels at Week 168<br>[units: log10 copies/mL]<br>Mean (Standard Deviation) | -3.79 (1.305) | -3.48 (1.629) |

Statistical Analysis 1 for Change From Baseline in log10 Plasma HBV DNA Levels at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.103 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Other [van Elteren] |
| | Comments | [Not specified] |

12. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168 |
| Measure Description | |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description

Non-completers = failure analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 52 |
| Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168<br>[units: U/mL]<br>Mean (Standard Deviation) | -26.8 (60.23) | -54.5 (141.63) |

Statistical Analysis 1 for Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.999 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Other [van Elteren] |
| | Comments | [Not specified] |

13. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168 |
| Measure Description | |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description

Non-completers = failure analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |

| | Description |
|---|---|
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 53 | 52 |
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168<br>[units: Percent of Participants] | 82.4 | 84.0 |

Statistical Analysis 1 for Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.781 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

14. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Normal ALT at Week 168 |
| Measure Description | ULN for males = 43 U/L; ULN for females = 34 U/L |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description

Non-completers = failure analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 50 | 50 |
| Percentage of Participants With Normal ALT at Week 168<br>[units: Percent of Participants] | 74.0 | 74.0 |

Statistical Analysis 1 for Percentage of Participants With Normal ALT at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.936 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

15. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Normalized ALT at Week 168 |
| Measure Description | Subjects with elevated ALT at baseline that return to normal by Week 48. |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description
[Not Specified]

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 25 | 24 |
| Percentage of Participants With Normalized ALT at Week 168<br>[units: Percent of Participants] | 68.0 | 70.8 |

Statistical Analysis 1 for Percentage of Participants With Normalized ALT at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.784 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

16. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Hepatitis B Early Antigen (HBeAg) Loss at Week 168 |
| Measure Description | Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline. |
| Time Frame | 168 weeks |
| Safety Issue? | No |

| | |
|---|---|
| Anticipated Reporting Date | October 2011 |

Analysis Population Description
Non-completer = Failure Analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 37 | 37 |
| Hepatitis B Early Antigen (HBeAg) Loss at Week 168<br>[units: Percent of Participants] | 21.6 | 24.3 |

Statistical Analysis 1 for Hepatitis B Early Antigen (HBeAg) Loss at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.703 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

17. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168 |
| Measure Description | Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline. |
| Time Frame | 168 weeks |

| | |
|---|---|
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description
Non-completer = Failure Analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 51 | 51 |
| Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168<br>[units: Participants] | 1 | 0 |

Statistical Analysis 1 for Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.254 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

18. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | HBsAg Loss at Week 168 |
| Measure Description | Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline. |

| | |
|---|---|
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | October 2011 |

Analysis Population Description
[Not Specified]

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 51 | 51 |
| HBsAg Loss at Week 168<br>[units: Participants] | 1 | 0 |

Statistical Analysis 1 for HBsAg Loss at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.254 |
| | Comments | Controlling for baseline HBeAg status and prior lamivudine use. |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

19. Secondary Outcome Measure:

| | |
|---|---|
| Measure Title | Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168 |

| | |
|---|---|
| Measure Description | P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use. |
| Time Frame | 168 weeks |
| Safety Issue? | No |
| Anticipated Reporting Date | November 2011 |

Analysis Population Description

Non-completers = failure analysis

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Measured Values

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Number of Participants Analyzed | 51 | 50 |
| Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168<br>[units: Percent of Participants] | 80.4 | 78.0 |

Statistical Analysis 1 for Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168

| | | |
|---|---|---|
| Statistical Analysis Overview | Comparison Groups | Tenofovir DF, Emtricitibine/Tenofovir DF |
| | Comments | [Not specified] |
| | Non-Inferiority or Equivalence Analysis? | No |
| | Comments | [Not specified] |

| | | |
|---|---|---|
| Statistical Test of Hypothesis | P-Value | 0.878 |
| | Comments | [Not specified] |
| | Method | Cochran-Mantel-Haenszel |
| | Comments | [Not specified] |

## Reported Adverse Events

| | |
|---|---|
| Time Frame | 168 weeks |
| Additional Description | [Not specified] |

Reporting Groups

| | Description |
|---|---|
| Tenofovir DF | tenofovir DF 300 mg QD |
| Emtricitibine/Tenofovir DF | emtricitabine 200 mg / tenofovir DF 300 mg QD (combination tablet) |

Serious Adverse Events

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| | Affected/At Risk (%) | Affected/At Risk (%) |
| Total | 6/ | 10/ |
| Blood and lymphatic system disorders | | |
| Anaemia † | 1/53 (1.89%) | 0/52 (0%) |
| Cardiac disorders | | |
| Atrial Fibrillation * | 0/53 (0%) | 1/52 (1.92%) |
| Gastrointestinal disorders | | |
| Colitis ulcerative * | 1/53 (1.89%) | 0/52 (0%) |
| General disorders | | |
| Chest Pain [A] * | 1/53 (1.89%) | 0/52 (0%) |
| Oedema Peripheral [A] * | 1/53 (1.89%) | 0/52 (0%) |
| Infections and infestations | | |
| Appendicitis * | 0/53 (0%) | 1/52 (1.92%) |
| Chronic Sinusitis [A] * | 0/53 (0%) | 1/52 (1.92%) |
| Gastroenteritis * | 1/53 (1.89%) | 0/52 (0%) |
| Sepsis * | 0/53 (0%) | 1/52 (1.92%) |
| Investigations | | |

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| | Affected/At Risk (%) | Affected/At Risk (%) |
| Alanine Aminotransferase Increased [A] † | 0/53 (0%) | 2/52 (3.85%) |
| Musculoskeletal and connective tissue disorders | | |
| Intervertebral Disc Protrusion * | 0/53 (0%) | 1/52 (1.92%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | |
| Fibroadenoma of Breast * | 0/53 (0%) | 1/52 (1.92%) |
| Lymphoma * | 0/53 (0%) | 1/52 (1.92%) |
| Waldenstrom's Macroglobulinaemia * | 1/53 (1.89%) | 0/52 (0%) |
| Nervous system disorders | | |
| Carotid Arteriosclerosis * | 1/53 (1.89%) | 0/52 (0%) |
| Cerebrovascular Accident [A] * | 0/53 (0%) | 1/52 (1.92%) |
| Hemiparesis [A] * | 0/53 (0%) | 1/52 (1.92%) |
| Pain * | 0/53 (0%) | 1/52 (1.92%) |
| Psychiatric disorders | | |
| Alcoholism [A] * | 0/53 (0%) | 1/52 (1.92%) |
| Renal and urinary disorders | | |
| Renal failure * | 0/53 (0%) | 1/52 (1.92%) |
| Reproductive system and breast disorders | | |
| Bartholinitis * | 0/53 (0%) | 1/52 (1.92%) |
| Respiratory, thoracic and mediastinal disorders | | |
| Dyspnoea [A] * | 1/53 (1.89%) | 0/52 (0%) |
| Respiratory failure * | 0/53 (0%) | 1/52 (1.92%) |

† Indicates events were collected by systematic assessment.
* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA 10.1

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| | Affected/At Risk (%) | Affected/At Risk (%) |
| Total | 49/ | 42/ |
| Blood and lymphatic system disorders | | |
| Anaemia † | 3/53 (5.66%) | 1/52 (1.92%) |
| Gastrointestinal disorders | | |
| Abdominal Pain [A] * | 5/53 (9.43%) | 5/52 (9.62%) |
| Abdominal Pain Upper [A] * | 8/53 (15.09%) | 9/52 (17.31%) |
| Constipation * | 2/53 (3.77%) | 3/52 (5.77%) |
| Diarrhoea [A] * | 5/53 (9.43%) | 3/52 (5.77%) |
| Dyspepsia * | 4/53 (7.55%) | 2/52 (3.85%) |
| Gastroenteritis * | 3/53 (5.66%) | 1/52 (1.92%) |
| Haemorrhoids * | 3/53 (5.66%) | 1/52 (1.92%) |
| Nausea [A] * | 5/53 (9.43%) | 2/52 (3.85%) |
| General disorders | | |
| Asthenia [A] * | 7/53 (13.21%) | 2/52 (3.85%) |
| Fatigue [A] * | 9/53 (16.98%) | 9/52 (17.31%) |
| Immune system disorders | | |
| Seasonal allergy * | 2/53 (3.77%) | 3/52 (5.77%) |
| Infections and infestations | | |
| Bronchitis * | 3/53 (5.66%) | 7/52 (13.46%) |
| Influenza * | 3/53 (5.66%) | 1/52 (1.92%) |
| Nasopharyngitis [A] * | 16/53 (30.19%) | 12/52 (23.08%) |
| Upper respiratory tract infection * | 1/53 (1.89%) | 3/52 (5.77%) |
| Urinary Tract Infection [A] * | 5/53 (9.43%) | 4/52 (7.69%) |

| | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| | Affected/At Risk (%) | Affected/At Risk (%) |
| Investigations | | |
| Alanine Aminotransferase Increased † | 0/53 (0%) | 3/52 (5.77%) |
| Blood Creatine Phosphokinase Increased [A] † | 0/53 (0%) | 4/52 (7.69%) |
| Metabolism and nutrition disorders | | |
| Decreased appetite * | 3/53 (5.66%) | 1/52 (1.92%) |
| Musculoskeletal and connective tissue disorders | | |
| Arthralgia * | 2/53 (3.77%) | 5/52 (9.62%) |
| Back Pain * | 9/53 (16.98%) | 6/52 (11.54%) |
| Myalgia * | 3/53 (5.66%) | 1/52 (1.92%) |
| Pain in Extremity * | 2/53 (3.77%) | 4/52 (7.69%) |
| Nervous system disorders | | |
| Dizziness [A] * | 4/53 (7.55%) | 4/52 (7.69%) |
| Headache [B] * | 15/53 (28.3%) | 10/52 (19.23%) |
| Paraesthesia * | 0/53 (0%) | 3/52 (5.77%) |
| Psychiatric disorders | | |
| Depression * | 1/53 (1.89%) | 3/52 (5.77%) |
| Insomnia * | 1/53 (1.89%) | 3/52 (5.77%) |
| Respiratory, thoracic and mediastinal disorders | | |
| Cough * | 3/53 (5.66%) | 1/52 (1.92%) |
| Pharyngolaryngeal Pain [A] * | 8/53 (15.09%) | 3/52 (5.77%) |
| Skin and subcutaneous tissue disorders | | |
| Alopecia * | 3/53 (5.66%) | 1/52 (1.92%) |
| Pruritis * | 3/53 (5.66%) | 2/52 (3.85%) |

† Indicates events were collected by systematic assessment.
* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA 10.1

B Term from vocabulary, Dizziness

## Limitations and Caveats

The randomized and treated (RAT) analysis set includes all subjects who were ongoing at the time of analysis (i.e., those on blinded therapy and those who switched to open-label FTC/TDFdue to persistent viremia).

## More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Official Title: Stephen J. Rossi, PharmD
Organization: Gilead Sciences, Inc.
Phone: 650-522-4212
Email: stephen.rossi@gilead.com